Drug Discovery

In a world where Alzheimer’s disease continues to challenge medical science with its relentless progression and devastating impact on millions of lives, the search for effective treatments remains a top priority for researchers and pharmaceutical companies alike. Recent developments have sparked

In the rapidly evolving landscape of biotechnology, few companies have captured the imagination of investors and industry watchers quite like Recursion Pharmaceuticals (NASDARXRX). Headquartered in Salt Lake City, Utah, this clinical-stage “TechBio” firm is at the forefront of a paradigm shift,

What happens when a beacon of hope for millions battling multiple sclerosis (MS) dims in a single clinical trial? In a field where breakthroughs are rare and desperately needed, Contineum Therapeutics, a San Diego-based biotech firm, has hit a significant roadblock with their lead drug, PIPE-307,

Diving into the world of virology, we’re thrilled to speak with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development. With a deep understanding of technology and innovation in the industry, Ivan has been at the forefront of groundbreaking discoveries.

In the intricate landscape of drug discovery, pinpointing effective inhibitors for Protein Tyrosine Phosphatase 1B (PTP1B) stands as a monumental challenge with profound implications for treating metabolic disorders such as diabetes and obesity. PTP1B is a key player in regulating insulin signaling

In a landscape where lung cancer remains one of the most challenging diseases to treat, particularly for rare subsets of patients, a new development has sparked hope among clinicians and affected individuals alike. Bayer’s recently approved drug, sevabertinib, marketed as Hyrnuo, has gained